Impact of Blueberry Consumption on Gastrointestinal Health

NCT ID: NCT03934177

Last Updated: 2023-03-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-26

Study Completion Date

2023-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the impact of blueberry consumption on markers of gastrointestinal health including gut microbiota, intestinal permeability, and gut-derived inflammation in those vulnerable to a unhealthy gut milieu. All participants will consume a blueberry powder and a placebo in this crossover study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The commensal bacteria that reside in the human gut, known as the gut microbiota, is a complex system that modulates local gut homeostasis and systemic biological processes. Several environmental factors have been shown to influence the gut milieu (including microbiota), and thus both gastrointestinal and host health. Relevant to the current proposal is the influence of body weight, diet, and circadian rhythms. In the current study, the investigators propose to use these common disruptors of gastrointestinal health through recruiting obese shift workers with a low-fiber diet to identify if these disrupted individuals can benefit from blueberry intake. Specifically, the study objectives are to determine if 24 g whole blueberry powder consumed daily can beneficially modify intestinal permeability, gut microbiota, microbial metabolites, and both gut-derived and systemic inflammation in those most susceptible to a pro-inflammatory milieu. This will be accomplished through a 14-week crossover study in which 28 individuals will be randomized by treatment group order to 4 weeks of whole blueberry powder and placebo powder, with a 4-week wash out in between the treatment periods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Circadian Dysregulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This 14-week crossover study includes 4 weeks for each of the two supplementation periods (blueberries and placebo), with a 4-week wash out between.
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Participants, investigators, and statistician will blinded to treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blueberry powder

4 weeks of supplementation of 24 g whole blueberry powder

Group Type EXPERIMENTAL

Blueberry powder

Intervention Type DIETARY_SUPPLEMENT

Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.

Placebo powder

4 weeks of supplementation of 24 g placebo powder (maltodextrin)

Group Type PLACEBO_COMPARATOR

Placebo powder

Intervention Type DIETARY_SUPPLEMENT

A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blueberry powder

Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.

Intervention Type DIETARY_SUPPLEMENT

Placebo powder

A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* obese (BMI +/- 30.0 kg/m2)
* shift workers (shift work overnight (third shift) +/= 3 days/week for the past 3 months)
* 19-70 years of age

Exclusion Criteria

* patient history of gastrointestinal diseases except for hiatal hernia, GERD, or hemorrhoids, mild gastrointestinal symptoms
* elevated laboratory values from a comprehensive metabolic panel (CMP) and complete blood count (CBC) with the exception of glucose (+/= 126 mg/dL; if elevated, confirmed with HA1c of greater than or equal to 6.5%) and ALT, AST, or ALP over 2 times normal levels (to allow for mild elevations resulting from fatty liver often seen in obese) unless approved by study physician
* currently pregnant or plans to become pregnant during the study as determined by participant report
* antibiotic use within the last 12 weeks prior to enrollment
* presence of chronic metabolic disease (e.g., cardiovascular disease, diabetes, cancer) or per physician discretion
* recent (past 4 weeks) major change in dietary habits or a plan to have a major change in dietary habits during the study
* habitual blueberry consumption of more than 0.5 cups 2x/week or a 4-week washout period if consumes
* allergy or intolerance to blueberries
* consumption of supplemental fiber, probiotics or prebiotics without an appropriate 4-week washout period
* restrictive dietary patterns (e.g., ketogenic, Paleolithic) or a diet high in fiber (+/= 14 g/1000 kilocalories) to increase study result generalizability to the U.S. population (low-fiber diet), as well as provide another stimuli for gut leakiness
* unwillingness to consent to the study.
Minimum Eligible Age

19 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rush University Medical Center

OTHER

Sponsor Role collaborator

University of Nebraska

OTHER

Sponsor Role collaborator

University of Nebraska Lincoln

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Heather E Rasmussen, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska Lincoln

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Nebraska

Lincoln, Nebraska, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18557

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics and Gut Health
NCT01874301 COMPLETED NA